
- Pharmaceutical Technology-07-02-2016
- Volume 40
- Issue 7
Quality System for a Regulatory Affairs Department
Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses standard operating procedures for the regulatory affairs department.
Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses standard operating procedures for the regulatory affairs department.
Q: Our company’s quality unit performs internal audits of all departments that have to comply with healthcare regulations. During a recent internal audit of the regulatory affairs (RA) department, we noted that there were no standard operating procedures (SOPs) in place. The RA department has asked for our help and would like to know which SOPs they will have to create and follow. What advice can you give?
A: The RA department must embed SOPs within a quality management system and create a quality unit responsible for maintaining it. RA departments perform activities that play a critical role in assuring product quality and patient health. Activities include preparing submissions (e.g., new drug applications or variations), label management, and pharmacovigilance. Regulatory authorities typically inspect RA departments because of complaints, recalls, or other non-conformance factors.
In terms of implementation, many companies will create a central regulatory affairs unit (e.g., RA headquarters) with supporting RA departments distributed across other locations. These are typically referred to as affiliates. The SOPs listed in Table I are typically associated with the RA headquarters, whereby those listed in Table II are typically adopted by the RA affiliates.
To sum up, controlled and documented processes assure compliance with the regulations, enhance the quality of all deliverables, and ultimately assure patient safety. For that reason, RA departments need to create, adopt, and implement the SOPs that cover their regulated activities.
Article DetailsPharmaceutical Technology
Vol. 40, No. 7
Pages: 73–74
Citation
When referring to this article, please cite it as S. Schmitt, “Quality System for a Regulatory Affairs Department," Pharmaceutical Technology 40 (7) 2016.
Articles in this issue
almost 10 years ago
FDA and Manufacturers Intensify Concerns about Data Integrityalmost 10 years ago
Planning a Biologics Facility Start Upalmost 10 years ago
Solid-Dosage Packaging Trendsalmost 10 years ago
Data Integrity Challenges in Manufacturingalmost 10 years ago
Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017almost 10 years ago
Cleaning Bioreactors and Fermenters with CIP Systemsalmost 10 years ago
Maximize Efficiency in Tooling Maintenancealmost 10 years ago
Recognizing Pharma Industry Excellencealmost 10 years ago
Expanding the Chiral Toolboxalmost 10 years ago
Modular Bioreactor Simplifies Process Development



